Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

186

Participants

Timeline

Start Date

February 27, 2018

Primary Completion Date

September 30, 2024

Study Completion Date

September 30, 2024

Conditions
Triple Negative Breast Neoplasms
Interventions
DRUG

ladiratuzumab vedotin

Given into the vein (IV; intravenously)

DRUG

Pembrolizumab

IV infusion every 3 weeks

Trial Locations (50)

10065

Weill Cornell Medicine, New York

13496

CHA Bundang Medical Center, Seongnam

15006

Complejo Hospitalario Universitario La Coruna, A Coruña

15232

University of Pittsburgh Medical Center (UPMC)/Hillman Cancer Center, Pittsburgh

19713

Helen F. Graham Cancer Center / Christiana Care Health Systems, Newark

21201

University of Maryland, Baltimore

22903

University of Virginia, Charlottesville

23007

Complejo Hospitalario de Jaen, Jaén

28033

MD Anderson Cancer Center - Madrid, Madrid

28034

Hospital Ruber Internacional, Madrid

28041

Hospital Universitario 12 de Octubre, Madrid

28050

HM Centro Integral Oncologico Clara Campal, Madrid

28223

Hospital Universitario Quironsalud Madrid, Pozuelo de Alarcón

30309

Piedmont Cancer Institute, Atlanta

30322

Winship Cancer Institute / Emory University School of Medicine, Atlanta

32804

AdventHealth Cancer Institute, Orlando

33176

Miami Cancer Institute at Baptist Health, Inc., Miami

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

35249

University of Alabama at Birmingham, Birmingham

45136

Kliniken Essen-Mitte - Evang. Huyssens-Stiftung, Essen

46236

Marien Hospital Bottrop, Bottrop

49201

Pusan National University Hospital, Busan

53111

Gynakologisches Zentrum Bonn Friedensplatz, Bonn

55407

Allina Health Cancer Institute, Minneapolis

60153

Cardinal Bernardin Cancer Center / Loyola University Medical Center, Maywood

60426

Ingalls Cancer Care / Ingalls Memorial Hospital, Harvey

64111

Saint Luke's Cancer Institute LLC, Kansas City

75246

Texas Oncology - DFW, Dallas

77024

Texas Oncology - Houston Memorial City, Houston

78212

Texas Oncology - San Antonio Medical Center Northeast, San Antonio

80012

Rocky Mountain Cancer Centers - Aurora, Aurora

80337

Klinikum der Universitat Munchen, München

80637

Rotkreuzklinikum Munich, Munich

81675

Klinikum Rechts der Isar der Technischen Universitaet Muenchen, München

87131

New Mexico Cancer Center, Albuquerque

90048

Cedars Sinai Medical Center / Samuel Oschin Comprehensive Cancer Institute, Los Angeles

91054

Universitatsklinikum Erlangen, Erlangen

92868

Chao Family Comprehensive Cancer Center University of California Irvine, Orange

University of California Irvine - Newport, Orange

06856

The Whittingham Cancer Center / Norwalk Hospital, Norwalk

07932

Summit Medical Group, Florham Park

98109-1023

Fred Hutchinson Cancer Center / Seattle Cancer Care Alliance / University of Washington, Seattle

06847

Stadtisches Klinikum Dessau, Dessau

01802

Korea Cancer Center Hospital, Seoul

03080

Seoul National University Hospital, Seoul

03722

Severance Hospital, Yonsei University Health System, Seoul

06351

Samsung Medical Center, Seoul

08003

Hospital del Mar, Barcelona

08035

Hospital Universitari Vall d'Hebron, Barcelona

08907

L'Institut Catala d'Oncologia, L'Hospitalet de Llobregat

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Seagen Inc.

INDUSTRY

NCT03310957 - Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer | Biotech Hunter | Biotech Hunter